Market Research Report
Colorectal Cancer - Global Market Outlook (2017-2026)
|Published by||Stratistics Market Research Consulting||Product code||907678|
|Published||Content info||137 Pages
Delivery time: 2-3 business days
|Colorectal Cancer - Global Market Outlook (2017-2026)|
|Published: August 19, 2019||Content info: 137 Pages||
According to Stratistics MRC, the Global Colorectal Cancer Market is accounted for $9.22 billion in 2017 and is expected to reach $13.01 billion by 2026 growing at a CAGR of 3.9% during the forecast period. Introduction of new and improved therapies and drugs, the rising uptake of higher-priced branded therapies, and several initiatives by governments and private organizations are some of the factors fuelling the market growth. However, factors such as the reluctance toward colorectal cancer medications on the part of patients and a lack of awareness in many parts of the world will pose a threat to the growth of the overall market.
Colorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiator between colon cancer and rectal cancer is the location of the primary tumor, but identical etiology and similar risk factors and symptoms mean that they are often grouped together. CRC is believed to arise as a result of interactions between inherited and environmental factors. Despite improved prognosis of CRC patients in the last decade following advances in treatment options, survival rates still lag behind those of breast and prostate cancer patients.
Based on therapies & drugs, the increasing awareness for treating colorectal cancer by chemotherapy and immunotherapy propels the industry growth during the forecast period. By Geography, North America is a key region in the market and estimated to have a lucrative growth in terms of demand and revenue. This market is fueled by a number of factors, the primary one being greater prevalence of colorectal cancer.
Some of the key players profiled in the Colorectal Cancer market include Abbott Laboratories, Amgen Inc., Clinical Genomics, EDP Biotech, Epigenomics AG, Hoffmann-La Roche AG, Novigenix SA, Quest Diagnostics, Sanofi SA, Siemens Healthineers and VolitionRX.
NOTE: The tables for North America, Europe, APAC, Middle East, Latin America, and Rest of the World Regions are also represented in the same manner as above.